New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
14:35 EDTBCRXNIAID exercises option under agreement with BioCryst
BioCryst Pharmaceuticals disclosed that on June 17 the company and the National Institute of Allergy and Infectious Diseases, or NIAID, amended their agreement dated September 12, 2013 for the development of BCX4430. NIAID exercised Option 6 under the agreement to conduct drug product development activities relating to the development of an IV formulation of BCX4430, including preformulation and stability studies and the manufacture of non-GMP drug substance. Pursuant to the option, NIAID released an additional $1.89M to the company and all other terms and conditions of the agreement remain unchanged, BioCryst said.
News For BCRX From The Last 14 Days
Check below for free stories on BCRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for BCRX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use